Direct Acting Antivirals

ApprovedSmall molecule

PPost Graduate Institute of Medical Education and Research, Chandigarh

Direct Acting Antivirals is one of 94 small molecule programs targeting Chronic Hepatitis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic HepatitisActive, not recruiting

Kidney TransplantActive, not recruiting

Hepatitis CActive, not recruiting

Chronic HepatitisPreclinical

Active, not recruiting

Kidney TransplantApproved

Active, not recruiting

Hepatitis CPreclinical

Active, not recruiting

Competition

Competitive Landscape

624 competitors in Chronic Hepatitis

#DrugCompanyPhaseTrials

Direct Acting Antivirals

PPost Graduate Institute of Medical Education and Research, Chandigarh

Approved

2 2

PEG-Intron

Merck & Co.

Preclinical

43 3

Sovaldi

Gilead

Preclinical

34 4

Virazole

CConrado Roberto Hoffmann Filho

Preclinical

199 5

Incivek

Vertex Pharmaceuticals

Preclinical

10 6

Intron a

Sanofi

Preclinical

7 7

Roferon-a

Roche

Preclinical

3 8

Medrol

Pfizer

Preclinical

1 9

Dasabuvir

AbbVie

Preclinical

7 10

SOF/VEL

Gilead

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Recruiting

Hepatitis C

NCT05368974

Clinical

Trials by Indication[1]

Hepatitis C5 trials

The Treatment in Pregnancy for Hepatitis C ("TiP-HepC") Registry

Recruiting·TThe Task Force for Global Health··NCT05368974·100 enrolled

Hepatitis C Positive Donor Into Hepatitis C Negative Recipients

Withdrawn·UUniversity of Maryland, Baltimore·Phase 1·NCT03702218

Treatment of Hepatitis c by Using Direct-acting Antiviral

Unknown status·TTanta University··NCT05372874·50 enrolled

Show 2 more trials

Management of Patients With Hepatitis C in a Public Health Care Setting: The Punjab Model

Unknown status·PPost Graduate Institute of Medical Education and Research, Chandigarh·N/A·NCT03488485·50,000 enrolled

An Observational Study of the Safety of Direct-acting Antivirals in Patients With Hepatitis C

Completed·KKaiser Permanente··NCT03423641·33,808 enrolled

Chronic Hepatitis2 trials

Frequency of Anxiety and Depression in Chronic Hepatitis C Patients Recieving Direct-Acting Antiviral Agents

Unknown status·—··NCT03894696·200 enrolled

DAA Therapy in Pediatric Patients With Chronic Hepatitis C

Unknown status·PPost Graduate Institute of Medical Education and Research, Chandigarh·N/A·NCT03481036·100 enrolled

Kidney Transplant1 trial

HCV + to HCV - Kidney Transplant

Withdrawn·MMassachusetts General Hospital·Phase 4·NCT04320290

HCV1 trial

HCV RAS Testing in Public Health Programs

Unknown status·PPost Graduate Institute of Medical Education and Research, Chandigarh··NCT04242433·200 enrolled

Treatment1 trial

Possible Differences in HCC Course Depending on DAA Treatment

Unknown status·MMedical University of Warsaw··NCT05376943·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Direct Acting Antivirals. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Direct Acting Antivirals compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Direct Acting Antivirals. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Post Graduate Institute of Medical Education and Research, Chandigarh company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: PPost Graduate Institute of Medical Education and Research, Chandigarh

Direct Acting Antivirals

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Hepatitis C5 trials

Chronic Hepatitis2 trials

Kidney Transplant1 trial

HCV1 trial

Treatment1 trial

References

Drug Info

Quick Facts

Related News